The most common adverse events in the treatment phase were injection-site reaction ( no patients with placebo vs three patients with @ MIU and @ MIU vs two patients with @ MIU ) and influenza-like syndrome ( no patients with placebo vs one patient with @ MIU and @ MIU vs four patients with @ MIU ) .